Cordis Corporation, a leading player in the medical device industry, is headquartered in the United States. Founded in 1959, the company has established itself as a pioneer in cardiovascular and endovascular solutions, focusing on innovative products that enhance patient outcomes. With a strong presence in North America, Europe, and Asia, Cordis is renowned for its advanced catheter and stent technologies. The company’s core offerings include a range of vascular access devices and interventional solutions, distinguished by their quality and efficacy. Cordis has achieved significant milestones, including the development of groundbreaking products that have set industry standards. As a trusted name in healthcare, Cordis Corporation continues to strengthen its market position through a commitment to innovation and excellence in patient care.
How does Cordis Corporation's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Cordis Corporation's score of 70 is higher than 83% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Cordis Corporation, headquartered in the US, currently does not have specific carbon emissions data available for recent years. As a current subsidiary of Cardinal Health, Inc., any emissions data or climate commitments would be inherited from this parent organisation. Cordis Corporation has not publicly disclosed any specific reduction targets or initiatives related to the Science Based Targets initiative (SBTi) or other climate pledges. The absence of detailed emissions data suggests that the company may still be in the process of establishing its own climate strategy or reporting framework. As part of its corporate family, Cordis Corporation may align with Cardinal Health, Inc.'s sustainability efforts, which could include broader industry commitments to reduce carbon footprints and enhance environmental stewardship. However, without specific data or targets from Cordis itself, it is challenging to provide a comprehensive overview of its climate commitments.
Access structured emissions data, company-specific emission factors, and source documents
| 2009 | 2010 | 2016 | 2017 | 2018 | 2019 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 148,856,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 
| Scope 2 | 212,644,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 
| Scope 3 | - | - | - | - | 00,000,000 | - | - | - | 00,000,000,000 | 00,000,000,000 | 
Cordis Corporation's Scope 3 emissions, which increased by 5% last year and increased significantly since 2018, demonstrating supply chain emissions tracking. Nearly all of their carbon footprint comes from suppliers and value chain emissions, representing nearly all emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 93% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Cordis Corporation has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.